Pulmonary hypertension in pediatric and neonatal intensive care unit. Part II: Diagnosis and treatment;Hypertension pulmonaire de l'enfant et du nouveau-né en réanimation. Partie II: diagnostic et traitement

Archives de Pediatrie

Volumn 18, Issue 2, 2011, Pages 195-203

  Dumas de la Roque, E ^a,b,c   Storme, L ^d   Mauriat, P ^e   Bonnet, S ^f  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b Centre of Clinical Investigation Clinical Epidemiology   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e HAUT LÉVÊQUE HOSPITAL   (France)

^f UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; NITRIC OXIDE; PROSTACYCLIN; SILDENAFIL;

ACIDOSIS; CONGENITAL HEART MALFORMATION; DRUG EFFICACY; ECHOGRAPHY; HEART LEFT VENTRICLE FAILURE; HEART RIGHT VENTRICLE; HEART SEPTUM DEFECT; HEMODYNAMICS; HUMAN; HYPERCAPNIA; HYPOXEMIA; INTENSIVE CARE UNIT; LUNG ARTERY PRESSURE; LUNG VENTILATION; NEWBORN INTENSIVE CARE; OXYGENATION; PULMONARY HYPERTENSION; PULMONARY VALVE INSUFFICIENCY; RESPIRATORY TRACT DISEASE; SHORT SURVEY; STRESS; TREATMENT PLANNING; TRICUSPID VALVE REGURGITATION;

EID: 79251629539     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcped.2010.11.001     Document Type: Short Survey

References (66)

1. Milan A., Magnino C., Veglio F. Echocardiographic indexes for the non-invasive evaluation of pulmonary hemodynamics. J Am Soc Echocardiogr 2010, 23:225-239. [quiz 332-4].
2. Bendjelid K., Romand J.A., Walder B., et al. Correlation between measured inferior vena cava diameter and right atrial pressure depends on the echocardiographic method used in patients who are mechanically ventilated. J Am Soc Echocardiogr 2002, 15:944-949.
3. Nakao S., Come P.C., McKay R.G., et al. Effects of positional changes on inferior vena caval size and dynamics and correlations with right-sided cardiac pressure. Am J Cardiol 1987, 59:125-132.
4. Simonson J.S., Schiller N.B. Sonospirometry: a new method for non invasive estimation of mean right atrial pressure based on two-dimensional echographic measurements of the inferior vena cava during measured inspiration. J Am Coll Cardiol 1988, 11:557-564.
5. Abbas A., Lester S., Moreno F.C., et al. Non invasive assessment of right atrial pressure using Doppler tissue imaging. J Am Soc Echocardiogr 2004, 17:1155-1160.
6. Dabestani A., Mahan G., Gardin J.M., et al. Evaluation of pulmonary artery pressure and resistance by pulsed Doppler echocardiography. Am J Cardiol 1987, 59:662-668.
7. Naeije R., Torbicki A. More on the non-invasive diagnosis of pulmonary hypertension: Doppler echocardiography revisited. Eur Respir J 1995, 8:1445-1449.
8. Thibault H.B., Kurtz B., Raher M.J., et al. Non invasive assessment of murine pulmonary arterial pressure: validation and application to models of pulmonary hypertension. Circ Cardiovasc Imaging 2010, 3:157-163.
9. Barst R.J., McGoon M., Torbicki A., et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004, 43:40S-47S.
10. Feiterna-Sperling C., Huseman D., Timme J., et al. Resolution of human immunodeficiency virus type 1 infection-related severe pulmonary hypertension in a very low-birth-weight infant. Pediatr Infect Dis J 2008, 27:564-567.
11. Willems A., Benne C.A., Timmer A., et al. Fatal illness associated with pulmonary hypertension in a neonate caused by intrauterine echovirus 11 infection. Am J Perinatol 2006, 23:59-61.
12. Kinsella J.P., Abman S.H. Recent developments in the pathophysiology and treatment of persistent pulmonary hypertension of the newborn. J Pediatr 1995, 126:853-864.
13. Alameh J., Bachiri A., Devisme L., et al. Alveolar capillary dysplasia: a cause of persistent pulmonary hypertension of the newborn. Eur J Pediatr 2002, 161:262-266.
14. Jaillard S.M., Godart F.R., Rakza T., et al. Acquired pulmonary vein stenosis as a cause of life-threatening pulmonary hypertension. Ann Thorac Surg 2003, 75:275-277.
15. Balanos G.M., Talbot N.P., Dorrington K.L., et al. Human pulmonary vascular response to 4h of hypercapnia and hypocapnia measured using Doppler echocardiography. J Appl Physiol 2003, 94:1543-1551.
16. Hyman A.L., Woolverton W.C., Guth P.S., et al. The pulmonary vasopressor response to decreases in blood pH in intact dogs. J Clin Invest 1971, 50:1028-1043.
17. Barer G.R., Bee D., Wach R.A. Contribution of polycythaemia to pulmonary hypertension in simulated high altitude in rats. J Physiol 1983, 336:27-38.
18. Machado R.F., Mack A.K., Martyr S., et al. Severity of pulmonary hypertension during vaso-occlusive pain crisis and exercise in patients with sickle cell disease. Br J Haematol 2007, 136:319-325.
19. Smith T.G., Balanos G.M., Croft Q.P., et al. The increase in pulmonary arterial pressure caused by hypoxia depends on iron status. J Physiol 2008, 586:5999-6005.
20. Houfflin-Debarge V., Delelis A., Jaillard S., et al. Effects of nociceptive stimuli on the pulmonary circulation in the ovine fetus. Am J Physiol Regul Integr Comp Physiol 2005, 288:R547-R553.
21. Houfflin Debarge V., Sicot B., Jaillard S., et al. The mechanisms of pain-induced pulmonary vasoconstriction: an experimental study in fetal lambs. Anesth Analg 2007, 104:799-806.
22. Roberts D.H., Lepore J.J., Maroo A., et al. Oxygen therapy improves cardiac index and pulmonary vascular resistance in patients with pulmonary hypertension. Chest 2001, 120:1547-1555.
23. Azarow K., Messineo A., Pearl R., et al. Congenital diaphragmatic hernia - a tale of two cities: the Toronto experience. J Pediatr Surg 1997, 32:395-400.
24. Kerbaul F., Rondelet B., Motte S., et al. Effects of norepinephrine and dobutamine on pressure load-induced right ventricular failure. Crit Care Med 2004, 32:1035-1040.
25. Bradford K.K., Deb B., Pearl R.G. Combination therapy with inhaled nitric oxide and intravenous dobutamine during pulmonary hypertension in the rabbit. J Cardiovasc Pharmacol 2000, 36:146-151.
26. Hoffman T.M., Wernovsky G., Atz A.M., et al. Prophylactic intravenous use of milrinone after cardiac operation in pediatrics. Am Heart J 2002, 143:15-21.
27. Hoffman T.M., Wernovsky G., Atz A.M., et al. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation 2003, 107:996-1002.
28. Duggal B., Pratap U., Slavik Z., et al. Milrinone and low cardiac output following cardiac surgery in infants: is there a direct myocardial effect?. Pediatr Cardiol 2005, 26:642-645.
29. Bailey J.M., Hoffman T.M., Wessel D.L., et al. A population pharmacokinetic analysis of milrinone in pediatric patients after cardiac surgery. J Pharmacokinet Pharmacodyn 2004, 31:43-59.
30. Bassler D., Choong K., McNamara P., et al. Neonatal persistent pulmonary hypertension treated with milrinone: four case reports. Biol Neonate 2006, 89:1-5.
31. Paradisis M., Evans N., Kluckow M., et al. Pilot study of milrinone for low systemic blood flow in very preterm infants. J Pediatr 2006, 148:306-313.
32. Paradisis M., Jiang X., McLachlan A.J., et al. Population pharmacokinetics and dosing regimen design of milrinone in preterm infants. Arch Dis Child Fetal Neonatal Ed 2007, 92:F204-F209.
33. Paradisis M., Evans N., Kluckow M., et al. Randomized trial of milrinone versus placebo for prevention of low systemic blood flow in very preterm infants. J Pediatr 2009, 154:189-195.
34. Morgan J.P., Perreault C.L., Morgan K.G. The cellular basis of contraction and relaxation in cardiac and vascular smooth muscle. Am Heart J 1991, 121:961-968.
35. Jaillard S., Houfflin-Debarge V., Riou Y., et al. Effects of catecholamines on the pulmonary circulation in the ovine fetus. Am J Physiol Regul Integr Comp Physiol 2001, 281:R607-R614.
36. Liet J.M., Boscher C., Gras-Leguen C., et al. Dopamine effects on pulmonary artery pressure in hypotensive preterm infants with patent ductus arteriosus. J Pediatr 2002, 140:373-375.
37. Bouissou A., Rakza T., Klosowski S., et al. Hypotension in preterm infants with significant patent ductus arteriosus: effects of dopamine. J Pediatr 2008, 153:790-794.
38. Nishina H., Ozaki T., Hanson M.A., et al. Mechanisms of noradrenaline-induced vasorelaxation in isolated femoral arteries of the neonatal rat. Br J Pharmacol 1999, 127:809-812.
39. Tourneux P., Rakza T., Bouissou A., et al. Pulmonary circulatory effects of norepinephrine in newborn infants with persistent pulmonary hypertension. J Pediatr 2008, 153:345-349.
40. Jaillard S., Elbaz F., Bresson-Just S., et al. Pulmonary vasodilator effects of norepinephrine during the development of chronic pulmonary hypertension in neonatal lambs. Br J Anaesth 2004, 93:818-824.
41. Magnenant E., Jaillard S., Deruelle P., et al. Role of the alpha2-adrenoceptors on the pulmonary circulation in the ovine fetus. Pediatr Res 2003, 54:44-51.
42. Cutaia M., Friedrich P. Hypoxia-induced alterations of norepinephrine vascular reactivity in isolated perfused cat lung. J Appl Physiol 1987, 63:982-987.
43. Tulloh R.M., Dyamenahalli U., Stuart-Smith K., et al. Adrenoceptor-stimulated endothelium-dependent relaxation in porcine intrapulmonary arteries. Pulm Pharmacol 1994, 7:299-303.
44. Tritapepe L., Voci P., Cogliati A.A., et al. Successful weaning from cardiopulmonary bypass with central venous prostaglandin E1 and left atrial norepinephrine infusion in patients with acute pulmonary hypertension. Crit Care Med 1999, 27:2180-2183.
45. Royster R.L., Butterworth JFt, Prielipp R.C., et al. Combined inotropic effects of amrinone and epinephrine after cardiopulmonary bypass in humans. Anesth Analg 1993, 77:662-672.
46. 2, attenuates hypoxia-induced pulmonary vasoconstriction in newborn lambs. Pediatr Res 1986, 20:113-117.
47. Chang A.C., Zucker H.A., Hickey P.R., et al. Pulmonary vascular resistance in infants after cardiac surgery: role of carbon dioxide and hydrogen ion. Crit Care Med 1995, 23:568-574.
48. Macrae D.J., Field D., Mercier J.C., et al. Inhaled nitric oxide therapy in neonates and children: reaching a European consensus. Intensive Care Med 2004, 30:372-380.
49. Goldman A.P., Delius R.E., Deanfield J.E., et al. Nitric oxide might reduce the need for extracorporeal support in children with critical postoperative pulmonary hypertension. Ann Thorac Surg 1996, 62:750-755.
50. Miller O.I., Tang S.F., Keech A., et al. Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: a randomised double-blind study. Lancet 2000, 356:1464-1469.
51. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996, 334:296-302.
52. Turanlahti M.I., Laitinen P.O., Sarna S.J., et al. Nitric oxide, oxygen, and prostacyclin in children with pulmonary hypertension. Heart 1998, 79:169-174.
53. Rosenzweig E.B., Kerstein D., Barst R.J. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999, 3(99):1858-1865.
54. Lammers A.E., Hislop A.A., Flynn Y., et al. Epoprostenol treatment in children with severe pulmonary hypertension. Heart 2007, 93:739-743.
55. Widlitz A., Barst R.J. Pulmonary arterial hypertension in children. Eur Respir J 2003, 21:155-176.
56. Simonneau G., Barst R.J., Galie N., et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002, 165:800-804.
57. McLaughlin V., Humbert M., Coghlan G., et al. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford) 2009, 48:iii25-iii31.
58. Olschewski H., Simonneau G., Galie N., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002, 347:322-329.
59. Rimensberger P.C., Spahr-Schopfer I., Berner M., et al. Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms. Circulation 2001, 103:544-548.
60. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346:896-903.
61. Channick R.N., Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001, 358:1119-1123.
62. Galie N., Beghetti M., Gatzoulis M.A., et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006, 114:48-54.
63. Barst R.J., Ivy D., Dingemanse J., et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003, 73:372-382.
64. Rosenzweig E.B., Ivy D.D., Widlitz A., et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 2005, 46:697-704.
65. Maiya S., Hislop A.A., Flynn Y., et al. Response to bosentan in children with pulmonary hypertension. Heart 2006, 92:664-670.
66. Galie N., Ghofrani H.A., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005, 353:2148-2157.